This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutIntroducing Enbrel®Heritage of Enbrel®IndicationsTherapeutic IndicationsRheumatoid ArthritisJuvenile Idiopathic ArthritisPsoriatic ArthritisAxial SpondyloarthritisPsoriasis & Paediatric PsoriasisMechanism of actionMode of ActionHalf-lifeDosingDosingRheumatoid Arthritis, Psoriatic Arthritis & Axial SpondyloarthritisJuvenile Idiopathic ArthritisPsoriasisPaediatric PsoriasisAdministration & StorageAdministrationMYCLIC®StorageEfficacy & SafetyEfficacyRapid EffectivenessSustained EffectivenessEffectiveness With Monotherapy or Combination TherapySafetyTolerability Across IndicationsSummary of Prescribing InformationImmunogenicityImmunogenicity & Clinical ResponseImmunogenicity & Enbrel®Experience & InsightsExperience & InsightManufacturingPatient StoriesRheumatoid ArthritisPatient With an Increased Risk of Serious InfectionsMTX-IR PatientPatient Who Is Considering Starting a FamilyElderly-onset RA PatientYoung Patient Worried About the Lifelong Impact of RAYoung Patient Worried About Treatments That Lose Effectiveness Over TimeJuvenile Idiopathic ArthritisJuvenile PatientPatient Moving From Childhood to AdolescenceAxial SpondyloarthritisAS Patients With Heel EnthesitisAS Patients With Functional LimitationsAdvanced AS PatientsPsoriatic Arthritis & PsoriasisPsO Patient With Severe SymptomsPsO Patients With Cyclical SymptomsPsA Patient With Metabolic SyndromePsA Patient With Multiple Skin & Joint SymptomsSupport & ServicesSupport & ServicesUsing Enbrel®Summary of Prescribing InformationPatient ResourcesEventsMaterialsVideos

Elderly-onset RA Patient

Meet Pradeep, a 69-year-old elderly-onset RA patient,1-4 diagnosed just months after his retirement.

    

‘I’ve always been worried about my health. Having high blood pressure and high cholesterol,5,6 I’m really conscious about keeping everything under control’.

    

‘When I retired recently, I expected to be more relaxed. That’s when the shock diagnosis came. RA at the age of 69.3-4 It’s really made me uncertain as to how later life will be’.

    

Compared with younger RA patients, elderly-onset RA patients are >3× less likely to be treated with biologics.7,*

   

Note: This is a hypothetical case for representation purpose only.

     

Elderly patients such as Pradeep benefit from long-term disease control and better drug survival with Enbrel®1,2

  • Improvements in disease activity and function were sustained up to 4 years in elderly patients with recent-onset RA and up to 6 years with late-stage RA1,†

  • Risk of discontinuation due to severe adverse drug reactions in elderly patients was lower with Enbrel® compared to both adalimumab and infliximab2,‡

From subset analyses of 4 RCTs and 2 long-term extension studies that evaluated a total of 2402 patients with RA.1,†

    

Observed ACR Response in Recent-onset RA Patients Treated With Open-label Enbrel®1

    

    

Adapted from Bathon MJ, et al. 2006.

  

   

Please consult the LPD for contraindications, warnings, precautions and other important safety information.

    

    

Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which Enbrel® (etanercept) could be considered.

    

*From a prospective observational study of 665 patients diagnosed with early RA (symptomatic for <12 months) who were divided into 2 groups: young-onset (<58 years) and late-onset (≥58 years) and followed for over 5 years. Over 5 years, late-onset RA was associated with less frequent treatment with biologics compared with young-onset RA: 7.4% versus 24.6%, respectively, P<0.001.7

    

From subset analyses of 4 randomised controlled clinical studies (n=1353) and 2 long-term extension studies (n=1049) of Enbrel®.1

    

Study design: Bathon MJ, et al. 2006.

    

Study objectives included the assessments of: whether the efficacy and safety of Enbrel® are similar in elderly (≥65 years) and younger (<65 years) subjects; whether Enbrel® treatment is effective in both elderly and younger subjects who have recent-onset (early) RA or DMARD-refractory (late-stage) RA.1

    

For the extension studies, ACR responses were presented as ‘observed cases’. Time points were measured from baseline of the extension and did not include study drug exposure in the initial studies. All subjects in the extensions received Enbrel® 25 mg BIW.1

    

The ERA study (ERA, 016.0012), which compared Enbrel® and MTX therapy, was the sole study through which subjects entered the recent-onset RA extension. Efficacy assessments were measured relative to the baseline of the ERA study.1

    

From a 14-year retrospective longitudinal analysis of 146 patients with RA followed in an outpatient clinic starting bDMARDs after the age of 65 years.2

    

ACR, American College of Rheumatology; AS, ankylosing spondylitis; bDMARD, biologic disease-modifying antirheumatic drug; BIW, twice a week; DMARD, disease-modifying anti-rheumatic drug; ERA, Early Rheumatoid Arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; RCT, randomised controlled trial; SmPC, summary of product characteristics.

    

References:

Bathon JM, Fleischmann RM, Van der Heijde D, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006;33(2):234-243.Leon L, Gomez A, Vadillo C, et al. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol. 2018;36(1):29-35.Kobak S, Bes C. An autumn tale: geriatric rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(1):3-11.Enbrel. Local product document. Version LPDENB062021.Ruban TN, Jacob B, Pope JE, Keystone EC, Bombardier C, Kuriya B. The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative. Clin Rheumatol. 2016;35(3):759-763.Aurrecoechea E, Llorca Díaz J, Diez Lizuain ML, McGwin G Jr, Calvo-Alen J. Gender-associated comorbidities in rheumatoid arthritis and their impact on outcome: data from GENIRA. Rheumatol Int. 2017;37(4):479-485.Innala L, Berglin E, Möller B, et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2014;16(2):R94.

    

Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

    

PP-ENB-IND-0814 August 2022

    

Observed ACR Response in Recent-onset RA Patients Treated With Open-label Enbrel®2

Rheumatoid Arthritis
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-ENB-IND-0814

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​